SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

Medicine & Life Sciences

• Second Primary Neoplasms 100%
• Carrier Proteins 74%
• Mutation 49%
• Myelodysplastic Syndromes 37%
• Acute Myeloid Leukemia 31%
• Type I Trichorhinophalangeal Syndrome 21%
• Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 19%
• Monosomy Chromosome 7 17%
• Helsinki Declaration 16%
• Bone Marrow 16%
• Refractory Anemia with Excess of Blasts 15%
• Monosomy 15%
• Abnormal Karyotype 15%
• Ficoll 14%
• Chromosomes, Human, Pair 7 13%
• Myeloid Leukemia 13%
• Germ-Line Mutation 12%
• Ontario 11%
• Research Ethics Committees 11%
• Missense Mutation 11%
• Karyotype 11%
• Codon 10%
• Incidence 10%
• Italy 10%
• Canada 9%
• Epigenomics 9%
• Autoimmune Diseases 9%
• Chromosomes 8%
• Radiotherapy 7%
• Technology 7%
• Heart 7%
• Drug Therapy 6%
• DNA 6%